Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Renal function and nonrenal solid organ transplantation

Roy D Bloom, MD
Section Editor
Barbara Murphy, MB, BAO, BCh, FRCPI
Deputy Editor
Albert Q Lam, MD


As outcomes following nonrenal solid organ transplantation have improved, chronic kidney disease (CKD) has become an increasingly prevalent complication in this population [1-3]. CKD occurs despite advancements in immunosuppression and perioperative management, as well as attention to cardiovascular risk factors and infectious complications [4].

The development of CKD is associated with enhanced morbidity and mortality [5].

Issues relating to kidney function following nonrenal solid organ transplantation, including the evaluation of kidney function prior to nonrenal organ transplantation, are presented in this topic review. A review of calcineurin inhibitor nephrotoxicity is presented separately. (See "Cyclosporine and tacrolimus nephrotoxicity".)


As a general rule, the preoperative evaluation of kidney function in candidates for nonrenal solid organ transplantation should focus on an assessment for a past history of renal injury and dysfunction (including duration and prior reversibility), the degree of current kidney function, and the likelihood and rate of progression after solid organ transplantation. Patients who are likely to have stage 4 or stage 5 chronic kidney disease (CKD) early after nonrenal organ transplant or those with established primary renal disease that is likely to progress rapidly (thereby requiring chronic kidney replacement therapy shortly after transplant) should be listed for combined organ transplant. In an era of ever-increasing organ shortage and longer waiting times for kidneys, combined nonrenal and renal organ transplantation should be considered very judiciously. In 2016, the United Network of Organ Sharing (UNOS) approved a new policy that formalized the allocation of simultaneous liver-kidney (SLK) transplants, anticipated to go into effect in 2017 [6]. (See 'Approach in liver transplant candidates' below.)

The vast majority of patients with normal or mild impairment in kidney function should receive a nonrenal solid organ transplant alone.

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Oct 2017. | This topic last updated: Nov 25, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Miller BW. Chronic kidney disease in solid-organ transplantation. Adv Chronic Kidney Dis 2006; 13:29.
  2. Chandrakantan A, de Mattos AM, Naftel D, et al. Increasing referral for renal transplant evaluation in recipients of nonrenal solid-organ transplants: a single-center experience. Clin J Am Soc Nephrol 2006; 1:832.
  3. Srinivas TR, Stephany BR, Budev M, et al. An emerging population: kidney transplant candidates who are placed on the waiting list after liver, heart, and lung transplantation. Clin J Am Soc Nephrol 2010; 5:1881.
  4. O'Riordan A, Wong V, McCormick PA, et al. Chronic kidney disease post-liver transplantation. Nephrol Dial Transplant 2006; 21:2630.
  5. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931.
  6. Formica RN, Aeder M, Boyle G, et al. Simultaneous Liver-Kidney Allocation Policy: A Proposal to Optimize Appropriate Utilization of Scarce Resources. Am J Transplant 2016; 16:758.
  7. Bloom RD, Reese PP. Chronic kidney disease after nonrenal solid-organ transplantation. J Am Soc Nephrol 2007; 18:3031.
  8. Gonwa TA, Jennings L, Mai ML, et al. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl 2004; 10:301.
  9. Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol 2010; 52:605.
  10. Tanriover B, Mejia A, Weinstein J, et al. Analysis of kidney function and biopsy results in liver failure patients with renal dysfunction: a new look to combined liver kidney allocation in the post-MELD era. Transplantation 2008; 86:1548.
  11. Skluzacek PA, Szewc RG, Nolan CR 3rd, et al. Prediction of GFR in liver transplant candidates. Am J Kidney Dis 2003; 42:1169.
  12. Francoz C, Nadim MK, Baron A, et al. Glomerular filtration rate equations for liver-kidney transplantation in patients with cirrhosis: validation of current recommendations. Hepatology 2014; 59:1514.
  13. Proulx NL, Akbari A, Garg AX, et al. Measured creatinine clearance from timed urine collections substantially overestimates glomerular filtration rate in patients with liver cirrhosis: a systematic review and individual patient meta-analysis. Nephrol Dial Transplant 2005; 20:1617.
  14. Orlando R, Mussap M, Plebani M, et al. Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis. Clin Chem 2002; 48:850.
  15. Samyn M, Cheeseman P, Bevis L, et al. Cystatin C, an easy and reliable marker for assessment of renal dysfunction in children with liver disease and after liver transplantation. Liver Transpl 2005; 11:344.
  16. Artunc FH, Fischer IU, Risler T, Erley CM. Improved estimation of GFR by serum cystatin C in patients undergoing cardiac catheterization. Int J Cardiol 2005; 102:173.
  17. Xirouchakis E, Marelli L, Cholongitas E, et al. Comparison of cystatin C and creatinine-based glomerular filtration rate formulas with 51Cr-EDTA clearance in patients with cirrhosis. Clin J Am Soc Nephrol 2011; 6:84.
  18. De Souza V, Hadj-Aissa A, Dolomanova O, et al. Creatinine- versus cystatine C-based equations in assessing the renal function of candidates for liver transplantation with cirrhosis. Hepatology 2014; 59:1522.
  19. Davis CL, Feng S, Sung R, et al. Simultaneous liver-kidney transplantation: evaluation to decision making. Am J Transplant 2007; 7:1702.
  20. Davis CL, Gonwa TA, Wilkinson AH. Identification of patients best suited for combined liver-kidney transplantation: part II. Liver Transpl 2002; 8:193.
  21. Davis CL, Gonwa TA, Wilkinson AH. Pathophysiology of renal disease associated with liver disorders: implications for liver transplantation. Part I. Liver Transpl 2002; 8:91.
  22. Wadei HM, Geiger XJ, Cortese C, et al. Kidney allocation to liver transplant candidates with renal failure of undetermined etiology: role of percutaneous renal biopsy. Am J Transplant 2008; 8:2618.
  23. Thompson BC, Kingdon E, Johnston M, et al. Transjugular kidney biopsy. Am J Kidney Dis 2004; 43:651.
  24. Sam R, Leehey DJ, Picken MM, et al. Transjugular renal biopsy in patients with liver disease. Am J Kidney Dis 2001; 37:1144.
  25. Sam R, Chebrolu SB, Reyes CV, et al. Transjugular renal biopsy in an unconscious patient maintained on mechanical ventilation. Clin Nephrol 2003; 60:53.
  26. Labban B, Arora N, Restaino S, et al. The role of kidney biopsy in heart transplant candidates with kidney disease. Transplantation 2010; 89:887.
  27. McGuire BM, Julian BA, Bynon JS Jr, et al. Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med 2006; 144:735.
  28. Gonwa TA, McBride MA, Anderson K, et al. Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us? Am J Transplant 2006; 6:2651.
  29. Pham PT, Pham PC, Rastogi A, Wilkinson AH. Review article: current management of renal dysfunction in the cirrhotic patient. Aliment Pharmacol Ther 2005; 21:949.
  30. Pichler RH, Huskey J, Kowalewska J, et al. Kidney Biopsies May Help Predict Renal Function After Liver Transplantation. Transplantation 2016; 100:2122.
  31. Wadei HM, Heckman MG, Rawal B, et al. Renal outcomes of liver transplant recipients who had pretransplant kidney biopsy. Transplantation 2014; 98:1323.
  32. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109:1004.
  33. Schaffer JM, Chiu P, Singh SK, et al. Heart and combined heart-kidney transplantation in patients with concomitant renal insufficiency and end-stage heart failure. Am J Transplant 2014; 14:384.
  34. Karamlou T, Welke KF, McMullan DM, et al. Combined heart-kidney transplant improves post-transplant survival compared with isolated heart transplant in recipients with reduced glomerular filtration rate: Analysis of 593 combined heart-kidney transplants from the United Network Organ Sharing Database. J Thorac Cardiovasc Surg 2014; 147:456.
  35. Devineni R, McKenzie N, Keown P, et al. Cyclosporine in cardiac transplantation. Can J Surg 1984; 27:252.
  36. Bennett WM. Insights into chronic cyclosporine nephrotoxicity. Int J Clin Pharmacol Ther 1996; 34:515.
  37. Bennett WM, DeMattos A, Meyer MM, et al. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50:1089.
  38. Van Buren DH, Burke JF, Lewis RM. Renal function in patients receiving long-term cyclosporine therapy. J Am Soc Nephrol 1994; 4:S17.
  39. El Kossi MM, Ibrahim A, Lock TJ, El Nahas AM. Impact of cardiac transplantation on kidney function: a single- center experience. Transplant Proc 2003; 35:1527.
  40. van Gelder T, Balk AH, Zietse R, et al. Renal insufficiency after heart transplantation: a case-control study. Nephrol Dial Transplant 1998; 13:2322.
  41. Waser M, Maggiorini M, Binswanger U, et al. Irreversibility of cyclosporine-induced renal function impairment in heart transplant recipients. J Heart Lung Transplant 1993; 12:846.
  42. Greenberg A, Thompson ME, Griffith BJ, et al. Cyclosporine nephrotoxicity in cardiac allograft patients--a seven-year follow-up. Transplantation 1990; 50:589.
  43. Goldstein DJ, Zuech N, Sehgal V, et al. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression. Transplantation 1997; 63:664.
  44. Zaltzman JS, Pei Y, Maurer J, et al. Cyclosporine nephrotoxicity in lung transplant recipients. Transplantation 1992; 54:875.
  45. Greenberg A, Egel JW, Thompson ME, et al. Early and late forms of cyclosporine nephrotoxicity: studies in cardiac transplant recipients. Am J Kidney Dis 1987; 9:12.
  46. McKenzie N, Keown P, Stiller C, et al. Effects of cyclosporine on renal function following orthotopic heart transplantation. J Heart Transplant 1985; 4:400.
  47. Ziolkowski J, Paczek L, Senatorski G, et al. Renal function after liver transplantation: calcineurin inhibitor nephrotoxicity. Transplant Proc 2003; 35:2307.
  48. Lynn M, Abreo K, Zibari G, McDonald J. End-stage renal disease in liver transplants. Clin Transplant 2001; 15 Suppl 6:66.
  49. Platz KP, Mueller AR, Blumhardt G, et al. Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK 506-treated patients. Transpl Int 1994; 7 Suppl 1:S52.
  50. Platz KP, Mueller AR, Blumhardt G, et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994; 58:170.
  51. Pattison JM, Petersen J, Kuo P, et al. The incidence of renal failure in one hundred consecutive heart-lung transplant recipients. Am J Kidney Dis 1995; 26:643.
  52. Fisher NC, Nightingale PG, Gunson BK, et al. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 1998; 66:59.
  53. Sehgal V, Radhakrishnan J, Appel GB, et al. Progressive renal insufficiency following cardiac transplantation: cyclosporine, lipids, and hypertension. Am J Kidney Dis 1995; 26:193.
  54. Wilkinson AH, Cohen DJ. Renal failure in the recipients of nonrenal solid organ transplants. J Am Soc Nephrol 1999; 10:1136.
  55. Myers BD. Cyclosporine nephrotoxicity. Kidney Int 1986; 30:964.
  56. Puschett JB, Greenberg A, Holley J, McCauley J. The spectrum of ciclosporin nephrotoxicity. Am J Nephrol 1990; 10:296.
  57. Bertani T, Ferrazzi P, Schieppati A, et al. Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. Kidney Int 1991; 40:243.
  58. Myers BD, Ross J, Newton L, et al. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311:699.
  59. Schwarz A, Haller H, Schmitt R, et al. Biopsy-diagnosed renal disease in patients after transplantation of other organs and tissues. Am J Transplant 2010; 10:2017.
  60. Barton TD, Blumberg EA, Doyle A, et al. A prospective cross-sectional study of BK virus infection in non-renal solid organ transplant recipients with chronic renal dysfunction. Transpl Infect Dis 2006; 8:102.
  61. Schmid H, Burg M, Kretzler M, et al. BK virus associated nephropathy in native kidneys of a heart allograft recipient. Am J Transplant 2005; 5:1562.
  62. Limaye AP, Smith KD, Cook L, et al. Polyomavirus nephropathy in native kidneys of non-renal transplant recipients. Am J Transplant 2005; 5:614.
  63. Barber CE, Hewlett TJ, Geldenhuys L, et al. BK virus nephropathy in a heart transplant recipient: case report and review of the literature. Transpl Infect Dis 2006; 8:113.
  64. Jain A, Reyes J, Kashyap R, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000; 232:490.
  65. U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331:1110.
  66. Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001; 72:1934.
  67. Iwatsuki S, Esquivel CO, Klintmalm GB, et al. Nephrotoxicity of cyclosporine in liver transplantation. Transplant Proc 1985; 17:191.
  68. de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35:333.
  69. Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002; 35:1179.
  70. Sanchez EQ, Gonwa TA, Levy MF, et al. Preoperative and perioperative predictors of the need for renal replacement therapy after orthotopic liver transplantation. Transplantation 2004; 78:1048.
  71. Gonwa TA, Klintmalm GB, Levy M, et al. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995; 59:361.
  72. Jeyarajah DR, Gonwa TA, McBride M, et al. Hepatorenal syndrome: combined liver kidney transplants versus isolated liver transplant. Transplantation 1997; 64:1760.
  73. Marik PE, Wood K, Starzl TE. The course of type 1 hepato-renal syndrome post liver transplantation. Nephrol Dial Transplant 2006; 21:478.
  74. Cabezuelo JB, Ramírez P, Ríos A, et al. Risk factors of acute renal failure after liver transplantation. Kidney Int 2006; 69:1073.
  75. O'Riordan A, Wong V, McQuillan R, et al. Acute renal disease, as defined by the RIFLE criteria, post-liver transplantation. Am J Transplant 2007; 7:168.
  76. Sharma P, Goodrich NP, Schaubel DE, et al. Patient-specific prediction of ESRD after liver transplantation. J Am Soc Nephrol 2013; 24:2045.
  77. Simpson N, Cho YW, Cicciarelli JC, et al. Comparison of renal allograft outcomes in combined liver-kidney transplantation versus subsequent kidney transplantation in liver transplant recipients: Analysis of UNOS Database. Transplantation 2006; 82:1298.
  78. Fioretto P, Mauer SM, Bilous RW, et al. Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys. Lancet 1993; 342:1193.
  79. Fioretto P, Steffes MW, Mihatsch MJ, et al. Cyclosporine associated lesions in native kidneys of diabetic pancreas transplant recipients. Kidney Int 1995; 48:489.
  80. Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339:69.
  81. Fioretto P, Kim Y, Mauer M. Diabetic nephropathy as a model of reversibility of established renal lesions. Curr Opin Nephrol Hypertens 1998; 7:489.
  82. Brennan DC, Stratta RJ, Lowell JA, et al. Cyclosporine challenge in the decision of combined kidney-pancreas versus solitary pancreas transplantation. Transplantation 1994; 57:1606.
  83. Lindelöw B, Bergh CH, Herlitz H, Waagstein F. Predictors and evolution of renal function during 9 years following heart transplantation. J Am Soc Nephrol 2000; 11:951.
  84. Bourge RC, Naftel DC, Costanzo-Nordin MR, et al. Pretransplantation risk factors for death after heart transplantation: a multiinstitutional study. The Transplant Cardiologists Research Database Group. J Heart Lung Transplant 1993; 12:549.
  85. Radovancevic B, Birovljev S, Frazier OH, et al. Long-term follow-up of cyclosporine-treated cardiac transplant recipients. Transplant Proc 1990; 22:21.
  86. Herlitz H, Lindelöw B. Renal failure following cardiac transplantation. Nephrol Dial Transplant 2000; 15:311.
  87. Lewis RM, Van Buren CT, Radovancevic B, et al. Impact of long-term cyclosporine immunosuppressive therapy on native kidneys versus renal allografts: serial renal function in heart and kidney transplant recipients. J Heart Lung Transplant 1991; 10:63.
  88. Gonwa TA, Mai ML, Pilcher J, et al. Stability of long-term renal function in heart transplant patients treated with induction therapy and low-dose cyclosporine. J Heart Lung Transplant 1992; 11:926.
  89. Zietse R, Balk AH, vd Dorpel MA, et al. Time course of the decline in renal function in cyclosporine-treated heart transplant recipients. Am J Nephrol 1994; 14:1.
  90. Tinawi M, Miller L, Bastani B. Renal function in cardiac transplant recipients: retrospective analysis of 133 consecutive patients in a single center. Clin Transplant 1997; 11:1.
  91. Goral S, Ynares C, Shyr Y, et al. Long-term renal function in heart transplant recipients receiving cyclosporine therapy. J Heart Lung Transplant 1997; 16:1106.
  92. Cirillo M, De Santo LS, Pollastro RM, et al. Creatinine clearance and hemoglobin concentration before and after heart transplantation. Semin Nephrol 2005; 25:413.
  93. Arora S, Andreassen A, Simonsen S, et al. Prognostic importance of renal function 1 year after heart transplantation for all-cause and cardiac mortality and development of allograft vasculopathy. Transplantation 2007; 84:149.
  94. Deuse T, Haddad F, Pham M, et al. Twenty-year survivors of heart transplantation at Stanford University. Am J Transplant 2008; 8:1769.
  95. Al Aly Z, Abbas S, Moore E, et al. The natural history of renal function following orthotopic heart transplant. Clin Transplant 2005; 19:683.
  96. Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006; 6:1377.
  97. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult heart transplant report--2005. J Heart Lung Transplant 2005; 24:945.
  98. Alam A, Badovinac K, Ivis F, et al. The outcome of heart transplant recipients following the development of end-stage renal disease: analysis of the Canadian Organ Replacement Register (CORR). Am J Transplant 2007; 7:461.
  99. Villar E, Boissonnat P, Sebbag L, et al. Poor prognosis of heart transplant patients with end-stage renal failure. Nephrol Dial Transplant 2007; 22:1383.
  100. Lonze BE, Warren DS, Stewart ZA, et al. Kidney transplantation in previous heart or lung recipients. Am J Transplant 2009; 9:578.
  101. Gill J, Shah T, Hristea I, et al. Outcomes of simultaneous heart-kidney transplant in the US: a retrospective analysis using OPTN/UNOS data. Am J Transplant 2009; 9:844.
  102. Cassuto JR, Reese PP, Bloom RD, et al. Kidney transplantation in patients with a prior heart transplant. Transplantation 2010; 89:427.
  103. Broekroelofs J, Stegeman CA, Navis G, de Jong PE. Prevention of renal function loss after non-renal solid organ transplantation--how can nephrologists help to keep the kidneys out of the line of fire? Nephrol Dial Transplant 1999; 14:1841.
  104. Maurer JR, Tewari S. Nonpulmonary medical complications in the intermediate and long-term survivor. Clin Chest Med 1997; 18:367.
  105. Broekroelofs J, Navis GJ, Stegeman CA, et al. Long-term renal outcome after lung transplantation is predicted by the 1-month postoperative renal function loss. Transplantation 2000; 69:1624.
  106. Navis G, Broekroelofs J, Mannes GP, et al. Renal hemodynamics after lung transplantation. A prospective study. Transplantation 1996; 61:1600.
  107. Tsimaratos M, Viard L, Kreitmann B, et al. Kidney function in cyclosporine-treated paediatric pulmonary transplant recipients. Transplantation 2000; 69:2055.
  108. Ishani A, Erturk S, Hertz MI, et al. Predictors of renal function following lung or heart-lung transplantation. Kidney Int 2002; 61:2228.
  109. Canales M, Youssef P, Spong R, et al. Predictors of chronic kidney disease in long-term survivors of lung and heart-lung transplantation. Am J Transplant 2006; 6:2157.
  110. Groetzner J, Wittwer T, Kaczmarek I, et al. Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation. Transplantation 2006; 81:355.
  111. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343:230.
  112. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54:2060.
  113. Senior PA, Zeman M, Paty BW, et al. Changes in renal function after clinical islet transplantation: four-year observational study. Am J Transplant 2007; 7:91.
  114. Senior PA, Paty BW, Cockfield SM, et al. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant 2005; 5:2318.
  115. Fiorina P, Folli F, Zerbini G, et al. Islet transplantation is associated with improvement of renal function among uremic patients with type I diabetes mellitus and kidney transplants. J Am Soc Nephrol 2003; 14:2150.
  116. Bloom RD, Doyle AM. Kidney disease after heart and lung transplantation. Am J Transplant 2006; 6:671.
  117. Tzakis AG, Kato T, Levi DM, et al. 100 multivisceral transplants at a single center. Ann Surg 2005; 242:480.
  118. Ueno T, Kato T, Gaynor J, et al. Renal dysfunction following adult intestinal transplant under tacrolimus-based immunosuppression. Transplant Proc 2006; 38:1762.
  119. Ueno T, Kato T, Gaynor J, et al. Renal function after pediatric intestinal transplant. Transplant Proc 2006; 38:1759.
  120. Herlenius G, Fägerlind M, Krantz M, et al. Chronic kidney disease--a common and serious complication after intestinal transplantation. Transplantation 2008; 86:108.
  121. Stigant CE, Cohen J, Vivera M, Zaltzman JS. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 2000; 35:58.
  122. Hausberg M, Barenbrock M, Hohage H, et al. ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 1999; 33:862.
  123. Borchhardt K, Haas N, Yilmaz N, et al. Low dose angiotensin converting enzyme inhibition and glomerular permselectivity in renal transplant recipients. Kidney Int 1997; 52:1622.
  124. Traindl O, Falger S, Reading S, et al. The effects of lisinopril on renal function in proteinuric renal transplant recipients. Transplantation 1993; 55:1309.
  125. Bochicchio T, Sandoval G, Ron O, et al. Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensives. Kidney Int 1990; 38:873.
  126. Bunke M, Ganzel B. Effect of calcium channel antagonists on renal function in hypertensive heart transplant recipients. J Heart Lung Transplant 1992; 11:1194.
  127. Chan C, Maurer J, Cardella C, et al. A randomized controlled trial of verapamil on cyclosporine nephrotoxicity in heart and lung transplant recipients. Transplantation 1997; 63:1435.
  128. Fassi A, Sangalli F, Colombi F, et al. Beneficial effects of calcium channel blockade on acute glomerular hemodynamic changes induced by cyclosporine. Am J Kidney Dis 1999; 33:267.
  129. Elliott WJ, Murphy MB, Karp R. Long-term preservation of renal function in hypertensive heart transplant recipients treated with enalapril and a diuretic. J Heart Lung Transplant 1991; 10:373.
  130. Sanchez V, Delgado JF, Morales JM, et al. Chronic cyclosporine-induced nephrotoxiciy in heart transplant patients: long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine. Transplant Proc 2004; 36:2823.
  131. Israni A, Brozena S, Pankewycz O, et al. Conversion to tacrolimus for the treatment of cyclosporine-associated nephrotoxicity in heart transplant recipients. Am J Kidney Dis 2002; 39:E16.
  132. Pratschke J, Neuhaus R, Tullius SG, et al. Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation. Transplantation 1997; 64:938.
  133. Lucey MR, Abdelmalek MF, Gagliardi R, et al. A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. Am J Transplant 2005; 5:1111.
  134. Nankivell BJ, Chapman JR, Bonovas G, Gruenewald SM. Oral cyclosporine but not tacrolimus reduces renal transplant blood flow. Transplantation 2004; 77:1457.
  135. Klein IH, Abrahams A, van Ede T, et al. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002; 73:732.
  136. Annual Data Report of the US Organ Procurement and Transplantation Network. Preface. Am J Transplant 2014; 14 Suppl 1:5.
  137. De Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 2012; 12:3008.
  138. Asrani SK, Wiesner RH, Trotter JF, et al. De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant 2014; 14:356.
  139. Cassuto JR, Reese PP, Sonnad S, et al. Wait list death and survival benefit of kidney transplantation among nonrenal transplant recipients. Am J Transplant 2010; 10:2502.